

1  
2  
3  
4  
5  
6 1 **Abstract**  
7

8 2 **Background:** Repeated hospital admissions are prevalent in older people. The role  
9 3 of medication in repeated hospital admissions has not been widely studied. The  
10 4 hypothesis that medication-related risk factors for initial hospital admissions were  
11 5 also associated with repeated hospital admissions was generated.

12  
13 6 **Objectives:** To examine the association between medication-related risk factors and  
14 7 repeated hospital admissions in older people living with frailty.

15  
16 8 **Method:** A retrospective case-control study was carried out with 200 patients aged  
17 9  $\geq 75$  years with unplanned medical admissions into a large teaching hospital in  
18 10 England between January and December 2015. Demographic, clinical, and  
19 11 medication-related data were obtained from review of discharge summaries.  
20 12 Statistical comparisons were made between patients with 3 or more hospital  
21 13 admissions during the study period (cases) and those with 2 or fewer admissions  
22 14 (controls). Regressions were performed to establish independent predictors of  
23 15 repeated hospital admissions.

24  
25 16 **Results:** Participants had a mean age of 83.8 years (SD 5.68) and 65.5% were  
26 17 female. There were 561 admission episodes across the sample, with the main  
27 18 reasons for admissions recorded as respiratory problems (25%) and falls (17%).  
28 19 Univariate logistic regression revealed five medication-related risks to be associated  
29 20 with repeated hospital admissions: Hyper-polypharmacy (defined as taking  $\geq 10$   
30 21 medications) (OR 2.50,  $p < 0.005$ ); prescription of potentially inappropriate  
31 22 medications (PIMs) (OR 1.89;  $p < 0.05$ ); prescription of a diuretic (OR 1.87;  $p < 0.05$ );  
32 23 number of high risk medication (OR 1.29;  $p < 0.05$ ) and the number of 'when required'  
33 24 medication (OR 1.20;  $p < 0.05$ ). However, the effects of these risk factors became  
34 25 insignificant when comorbid disease was adjusted for in a multivariable model.

35  
36 26 **Conclusion:** Medication-related risk factors may play an important role in future  
37 27 repeated admission risk prediction models. The modifiable nature of medication-  
38 28 related risks factors highlights a real opportunity to improve health outcomes.

39  
40  
41 29 **Key words:** repeated hospital admissions, prediction model, polypharmacy,  
42 30 medication risks, potentially inappropriate medication.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

1  
2  
3  
4 Title:

5 Medication-related risk factors and its association with frequent admissions in frail  
6 elderly: a case control study.  
7

8 Authors: V-Lin Cheong<sup>a,c</sup>, Julie Sowter<sup>a</sup>, Andy Scally<sup>b</sup>, Neil Hamilton<sup>c</sup>, Ali Ali<sup>d,e</sup>,  
9 Jonathan Silcock<sup>a</sup>.  
10  
11

12  
13  
14 <sup>a</sup> University of Bradford, School of Pharmacy and Medical Sciences, Bradford, UK

15  
16 <sup>b</sup> University of Bradford, Faculty of Health Studies, Bradford, UK

17  
18 <sup>c</sup> Sheffield Teaching Hospitals Foundation Trust, Pharmacy Department

19  
20 <sup>d</sup> Sheffield Teaching Hospitals Foundation Trust, Directorate of Geriatric and Stroke Medicine

21  
22 <sup>e</sup> University of Sheffield, Faculty of Medicine Dentistry and Health, Sheffield, UK

23 Corresponding Author: Ms V-Lin Cheong; [v.cheong@bradford.ac.uk](mailto:v.cheong@bradford.ac.uk)  
24  
25

26  
27 Declarations of interest: None.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

## 1 Background

2 Older people living with frailty often experience frequent transitions of care due to  
3 high hospital admission rates.<sup>1</sup> Many older adults are living with at least two long-  
4 term conditions (multimorbidity)<sup>2</sup>, which require multiple medications to manage  
5 these conditions.<sup>3</sup> Patients living with frailty experience higher levels of adverse drug  
6 events due to a decline in physiological reserves.<sup>4</sup> Hospital readmission rate is often  
7 used as an indicator of health system performance <sup>5</sup>, and there is increasing  
8 evidence that hospital readmission is linked to worse patient outcomes.<sup>6</sup>

9 In the UK, emergency hospital readmission is defined as any repeated admission to  
10 hospital within 30 days of discharge.<sup>7</sup> This definition is used for the purpose of  
11 financial penalty for the National Health Service (NHS) in the UK. The desired  
12 outcome for this study is to examine the phenomenon of repeated hospital  
13 admissions in a longitudinal time period. This is important for the cohort of older  
14 people living with frailty as many of these patients are subjected to polypharmacy  
15 and are living with multi-morbidities. Therefore, their medical management is  
16 complex and the reason for admission may not always be immediately evident or  
17 attributable to a single disease state.<sup>8</sup> In addition, repeated hospital admissions  
18 affect the quality of life and patient satisfaction; and may reduce the quality of  
19 transitional care experienced.

20 Previous research has shown that medication can increase the risk of hospital  
21 admissions.<sup>9</sup> Therefore, we hypothesised that medication-related risk factors known  
22 to be associated with admissions, could be associated with repeated hospital  
23 admissions (RHAs) in the frail elderly. In 2013, it was estimated that emergency  
24 readmission cost the NHS approximately £2.4 billion a year.<sup>10</sup> The financial and  
25 clinical implications of hospital readmissions have prompted the development of  
26 predictive tools to identify individuals at risk of readmission.<sup>11</sup> More importantly,  
27 predictive risk tools provide an opportunity for clinicians to alter existing risk factors  
28 to mitigate such risks.<sup>12</sup> However, medications are often not included as a predictor  
29 in these tools, and could be an important modifiable risk factor which warrants further  
30 exploration. The aim of this research was to examine the association between  
31 medication-related risk factors and RHAs in frail elderly patients.

## 32 Method

### 33 Data source

34 Data for this study were obtained from the electronic discharge summary records of  
35 a large teaching hospital in Sheffield, South Yorkshire, which serves a population of  
36 approximately 1.7million people. Electronic discharge summaries contain  
37 demographic and clinical information including discharge medication lists.

## 38 Sample

39 A retrospective unmatched case-control method was used to approach routine data  
40 collected at the hospital between January and December 2015, from which two  
41 groups of frail elderly patients were identified and compared. The participants' frailty  
42 was not assessed directly as frailty was often not coded on hospital records and  
43 discharge summaries. Instead, we considered age and number of hospital  
44 admissions per year as proxies for 'frailty' in accordance with the Edmonton Frail  
45 Scale.<sup>13</sup> Group A (cases) included patients aged  $\geq 75$  years with more repeated  
46 hospital admissions (at least 3 during the study period) and Group B consisted of  
47 patients aged  $\geq 75$  years with fewer repeated hospital admission (less than 3  
48 admissions). The data were extracted from discharge summaries of 200 randomly  
49 selected patients. 100 patients were randomly selected from 838 patients for Group  
50 A, and 100 from 8933 patients for Group B. Random selection was carried out using  
51 an online random number generator.<sup>14</sup> We only considered admissions that were  
52 unplanned and medical in nature, excluding elective and surgical admissions.  
53 Additionally, we excluded admissions to psychiatry and oncology services.

## 54 Measurements

55 Demographic data such as age, sex, and marital status were extracted. The number  
56 of co-morbidities were extracted from records of patients' histories and recorded as a  
57 simple count of long term conditions. Socioeconomic status was estimated using  
58 neighbourhood level Index of Multiple Deprivation (IMD).<sup>15</sup> Data for medication-  
59 related risks were obtained from the second unplanned admission in the year for  
60 Group A, and first unplanned admission of the year for Group B. This was to ensure  
61 consistency across the sample: everyone in Group A had an admission before and  
62 after their second admission; everyone in Group B had a first admission. Risks  
63 recorded included:

- 64 • Number of medicines on discharge;
- 65 • Prescription of high risk medicine(s)<sup>16</sup>, which included: non-steroidal anti-  
66 inflammatory drugs (NSAIDs), antiplatelets, antiepileptics, hypoglycaemics,  
67 diuretics, inhaled corticosteroids, cardiac glycosides, beta-blockers and  
68 anticoagulants (including direct acting oral anticoagulants);
- 69 • Presence of potentially inappropriate medicine (PIM) according to Table 2 of  
70 the Beer's Criteria<sup>17</sup>;
- 71 • Medication changes (during hospital stay, as outlined on discharge summary)  
72 during second (group A) or first hospital admission (Group B)<sup>18</sup>;
- 73 • Whether the patient received supported discharge
- 74 • Whether the patient received any multi-compartment aid (MCA) to use on  
75 discharge<sup>19</sup>.

76 The number of medications on discharge was counted and participants assessed for  
77 hyper-polypharmacy (taking at least 10 medications). This definition is consistent

119  
120  
121 78 with Gnjjidic et al.<sup>20</sup> whilst a common definition of polypharmacy as 5 or more  
122 79 medications <sup>21</sup> was not appropriate for this sample because most of the participants  
123 80 (96%) were taking at least 5 medications.

124  
125  
126 81 PIM and high risk medicines were both recorded muly (yes/no) and as a count.  
127 82 Discharge destination was extracted from discharge summaries and coded as  
128 83 'discharged to home' (discharged directly home with no additional care facilities) or  
129 84 'supported discharge' (discharged to residential care homes, intermediate care  
130 85 services or with domiciliary care packages).

131  
132  
133 86 Ethical approval was not required as this was carried out as part of a service  
134 87 evaluation project at the Trust using routine data. All data were collected by one  
135 88 investigator, who had normal access to the data, and was subsequently anonymised  
136 89 to ensure confidentiality of the data.

## 138 90 **Statistical analyses**

139  
140  
141 91 Between groups comparisons (cases vs controls) were carried out using a chi-  
142 92 squared test for categorical variables and t-test for continuous variables (data was  
143 93 normally distributed). Subsequently, univariate and stepwise multivariable logistic  
144 94 regression modelling was undertaken to identify independent predictors of RHAs as  
145 95 well as the predictive value of the overall model. For a variable to be included in the  
146 96 multivariable model, the Wald test should be significant at the level of  $p < 0.05$  in  
147 97 single variable regression. Further, odds ratios (and 95% confidence intervals) were  
148 98 reported for each model variable. A multi-variable regression model was used to  
149 99 identify independent predictors of RHAs. Single variables were included in the model  
150 100 by strength of association defined by p-value and application of the logistic model  
151 101 rule of thumb of a minimum of 10 events per predictor variable (EPV).<sup>22</sup> To enhance  
152 102 the clinical utility of any subsequent risk prediction tools developed, variables  
153 103 available at the point of admission were included. Some important variables such as  
154 104 number of discharge medication and supported discharge, were not available at the  
155 105 point of admission but were included due to their significance. We carried out  
156 106 collinearity diagnostics on the regression model variables and found the collinearities  
157 107 among the predictors to be low. All statistical tests were carried out using SPSS  
158 108 version 22.

## 164 109 **Results**

165  
166  
167 110 The demographics of the patients are presented in Table 1. While this case control  
168 111 study did not apply the principles of 'matching', demographic characteristics of the  
169 112 two groups of patients were not significantly different.

170  
171 113 Participants in the sample had a mean age of 83.8 years (SD 5.68), were  
172 114 predominantly female (65.5%) and were commonly living alone (64%). Patients  
173  
174  
175  
176  
177

178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236

115 living in the most deprived areas had higher RHAs than those not living in the most  
116 deprived areas (OR = 1.88; 95% CI 1.04 – 3.40; Table 2).

117 **Table 1 Descriptive analysis of sample characteristics and variables**

<b>Variables</b>	<b>Overall</b>	<b>Higher Repeated admissions group (A)</b>	<b>Lower repeated admissions group (B)</b>	<b>Chi-square or t-test value</b>	<b>p-value</b>
<b>Age (years)</b> Mean (SD)	83.8 (5.68)	83.6 (5.67)	83.9 (5.71)	-0.397	0.692
<b>Sex</b>				1.792	0.181
Female	131(65.5%)	70 (70%)	61 (61%)		
Male	69 (34.5%)	30 (30%)	39 (39%)		
<b>Living with a spouse</b>				0.781	0.377
Yes	72 (36%)	33 (33%)	39 (39%)		
No	128 (64%)	67 (67%)	61 (61%)		
<b>Deprivation index</b>				4.55	0.208
Unclear (out of area)	8 (4%)	3 (3%)	5 (5%)		
Least deprived	55 (27.5%)	25 (25%)	30 (30%)		
Moderately deprived	69 (35%)	31 (31%)	38 (38%)		
Most deprived	68 (34%)	41 (41%)	27 (27%)		
<b>Co-morbidities (number of)</b> Mean (SD)	4.84 (2.35)	5.79 (2.29)	3.89 (2.01)	6.231	0.000
<b>Length of stay (days)</b> Mean (SD)	10.37 (11.95)	8.78 (9.36)	11.96 (13.95)	-1.893	0.060
<b>Discharge destination</b>				8.420	0.004
Home	148 (74%)	83 (83%)	65 (65%)		
Supported discharge	52 (26%)	17 (17%)	35 (35%)		
<b>Hyper-polypharmacy (≥ 10 medication)</b>				9.408	0.002
Yes	125 (62.5%)	73 (73%)	52 (52%)		
No	75 (37.5%)	27 (27%)	48 (48%)		
<b>Number of 'when required' medication</b> Mean (SD)	1.75 (1.58)	1.97 (1.71)	1.52 (1.42)	2.023	0.044
<b>Medication changed during hospital stay?</b>				0.000	1.000
Yes	156 (78%)	78 (78%)	78 (78%)		
No	44 (22%)	22 (22%)	22 (22%)		

237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295

Variables	Overall	Higher Repeated admissions group (A)	Lower repeated admissions group (B)	Chi-square or t-test value	p-value
<b>Presence of high risk medication?</b>					
Yes	171 (85.5%)	89 (89%)	82 (82%)		
No	29 (14.5%)	11 (11%)	18 (18%)	1.976	0.160
<b>High Risk Medication Class</b>					
NSAIDs	2 (1%)	2 (1%)	0 (0%)	2.020	0.155
Antiplatelets	84 (42%)	44 (44%)	40 (40%)	0.328	0.567
Anti-epileptics	29 (14.5%)	16 (16%)	13 (13%)	0.363	0.547
Hypoglycaemics	18 (9%)	11 (11%)	7 (7%)	0.977	0.323
Diuretics	83 (41.5%)	49 (49%)	34 (34%)	4.634	0.031
Inhaled corticosteroids	50 (25%)	30 (30%)	20 (20%)	2.667	0.102
Cardiac glycosides	26 (13%)	14 (14%)	12 (12%)	0.177	0.674
Beta-blockers	81 (40.5%)	44 (44%)	37 (37%)	1.017	0.313
Anti-coagulants	57 (28.5%)	31 (31%)	26 (26%)	0.613	0.434
<b>Number of high risk medication class</b>					
Mean (SD)	2.15 (1.45)	2.41 (1.46)	1.89 (1.39)	2.574	0.011
<b>Presence of PIM?</b>					
Yes	66 (33%)	40 (40%)	26 (26%)		
No	134 (67%)	60 (60%)	74 (74%)	4.432	0.035
<b>Number of PIMs</b>					
Mean (SD)	0.4 (0.64)	0.5 (0.70)	0.3 (0.56)	-2.225	0.027

118 NSAIDs: Non-Steroidal Anti-inflammatory Drugs; PIM: Potentially-Inappropriate Medication;

### 119 Admission-level characteristics

120 The reasons for admission were based on presenting complaints documented on  
121 discharge summary for each admission. Of the 200 patients, there were 561  
122 admissions with available information on presenting complaints over the course of 12  
123 months. The most common reasons for admission were consistent across both  
124 groups of patients. These were: respiratory problems (including respiratory tract  
125 infection and exacerbation of chronic pulmonary disease) (n=140; 25%); fall (n=97;  
126 17.3%); cardiovascular problems (including angina, heart failure and blood pressure  
127 problems) (n=76; 13.5%); and gastrointestinal problems (n=40; 7.1%).

### 128 Medication-related risks

129 Several medication-related risk factors were more prevalent in the RHAs group:  
130 number of comorbidities, supportive discharge, number of medication at discharge,

131 hyper-polypharmacy ( $\geq 10$  medications), number of ‘when required’ medication,  
 132 prescribed a diuretic, and prescribed a potentially inappropriate medication (PIM).  
 133 The proportion of participants with: polypharmacy ( $\geq 5$  medications), undergoing  
 134 medication changes, or were prescribed a high risk medicine, were similar in both  
 135 groups.

136 Single variable logistic regression revealed five medication-related risk factors that  
 137 were associated with statistically significant increased odds of RHAs. Hyper-  
 138 polypharmacy ( $\geq 10$  medications) increased the odds of RHAs by 2.5 times (95% CI  
 139 1.38 – 4.51;  $p=0.002$ ); along with prescription of potentially inappropriate  
 140 medications (PIMs) in accordance with Beers Criteria <sup>17</sup> (OR 1.89; 95% CI 1.04 –  
 141 3.46;  $p=0.036$ ), and number of ‘when required’ medication (OR 1.20; 95% CI 1.00 –  
 142 1.45;  $p=0.047$ ). The most common PIMs used by patients within the study were  
 143 amitriptyline (5.5%), solifenacin (5.5%), doxazosin (4%) and tamsulosin (4.5%).  
 144 Whilst the dichotomous outcome of being prescribed a high risk drug (of any drug  
 145 group) was not associated with RHAs, a cumulative effect of prescribing high risk  
 146 drugs did exist with a 29% increase in the odds of RHAs with every additional high  
 147 risk drug prescribed (OR 1.29; 95% CI 1.06 – 1.58). In addition, diuretic prescription  
 148 in particular was associated with RHAs (OR 1.87; 95% CI 1.06 – 3.30).

149 **Table 2: Results of single variable logistic regression (n=200) evaluating odds**  
 150 **of RHA with each variable; listed in descending order of strength of**  
 151 **association by p-value (strongest association at the top).**

Variable	Odds ratio	95% CI	p-value
Number of comorbidities	1.50	1.29 – 1.74	0.000
Hyper-polypharmacy $\geq 10$ medications	2.50	1.38 – 4.51	0.002
Discharge to home	2.63	1.35 – 5.11	0.004
Prescription of each additional high risk drug	1.29	1.06 – 1.58	0.012
Prescribed diuretics	1.87	1.06 – 3.30	0.032
Presence of PIM*	1.89	1.04 – 3.46	0.036
Deprivation index Most deprived	1.88	1.04 - 3.41	0.038
Number of PRN medication*	1.20	1.00 – 1.45	0.047
Length of stay (days)	0.98	0.95 – 1.00	0.068
Prescribed inhaled corticosteroids	1.71	0.90 – 3.29	0.104
Presence of high risk drugs	1.78	0.79 – 3.98	0.163
Gender (female)	1.49	0.83 – 2.68	0.182
Living with spouse	0.77	0.43 - 1.38	0.377
Use of compliance aid	1.16	0.63 – 2.17	0.635
Age on admission	0.99	0.94 – 1.04	0.690



355  
356  
357 \*PRN: 'when required'; PIM: Potentially Inappropriate Medication as defined by modified-Beers Criteria.  
358

359 Table 3: Multivariable logistic regression (n=200)

Variable	Odds ratio	95% CI	p-value
Number of comorbidities	1.512	1.274 – 1.794	0.000
Discharged to home	2.235	1.019 – 4.898	0.045
Living in the most deprived area(s)	1.841	0.916 – 3.700	0.087
Prescribed potentially inappropriate medicine(s)	1.795	0.876 – 3.677	0.110
Female	1.631	0.820 – 3.246	0.163
Number of PRN drugs	1.127	0.896 – 1.417	0.309
Number of high risk drugs	0.871	0.634 – 1.198	0.396
Prescribed diuretic(s)	1.424	0.614 – 3.302	0.411
Hyper-polypharmacy ( $\geq 10$ meds)	1.057	0.467 – 2.394	0.894
Age on admission	0.997	0.941 – 1.056	0.922

375  
376 154  
377  
378 155 The multivariable logistic regression model is presented in Table 3. After controlling  
379 156 for age, sex, deprivation index, discharge destination and comorbidities, none of the  
380 157 medication-related variables significantly predicted RHAs. The multivariable logistic  
381 158 regression model indicated that number of comorbidities and being discharged to  
382 159 home (without support) were significant predictors of RHAs. There was a greater  
383 160 than 50% increased odds of RHAs with the presence of each comorbid condition  
384 161 (95% CI 1.27 – 1.79), and a more than 2-fold increased odds of RHAs when  
385 162 patients were discharged directly home with no additional care facilities (95% CI 1.02  
386 163 - 4.90). Whilst being prescribed a PIM potentially increased the odds of RHAs by  
387 164 nearly 80%, this increase was not statistically significant (OR 1.80; 95% CI 0.88-  
388 165 3.68;  $p=0.110$ ). This regression model had a chi-square of 52.48 (DF=10) ( $p<0.001$ ),  
389 166 with model predictors “explaining” 30.8% of the variability of frequency of RHAs  
390 167 (Nagelkerke pseudo- $R^2 = 0.308$ ). The Hosmer-Lemeshow suggested good model  
391 168 fitting (chi square 7.07,  $df=8$ ,  $p=0.528$ ). The Receiver Operating Characteristics  
392 169 (ROC) Curve for the model had an AUC of 0.781.

## 398 170 Discussion

399  
400  
401 171 Comorbid diseases and non-supported discharge were significant predictors of  
402 172 repeated hospital admissions. Comorbidities was found to be associated with  
403 173 hospital readmissions in previous studies.<sup>23, 24</sup> The Charlson comorbidity index (CCI)  
404 174 is a commonly used measure of comorbidity in such studies, but involves a  
405 175 cumulative weighted scoring system to predict 10-year mortality risk. We did not  
406 176 utilise this as we endeavoured to use measures easily obtained whilst providing care  
407 177 by the bedside, i.e. simple cumulative number of comorbidities. The number of  
408 178 comorbid conditions may be an indication of a number of issues in this cohort of  
409  
410  
411  
412  
413

414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472

179 patients. The existence of multiple comorbid conditions (i.e. multimorbidity) can have  
180 an impact on disease management burden, increased levels of care complexity, and  
181 increased risk of experiencing fragmented care<sup>25, 26</sup>. In addition, multimorbidity was  
182 found to be associated with decline in functional status and subsequent frailty<sup>27</sup>. With  
183 this in mind, while presence of comorbid conditions may be a significant predictor of  
184 RHAs, perhaps it is also an indicator of wider issues such as complexity, instability of  
185 disease management, fragmented care, and disease burden.

186 In previous studies, appropriate discharge support was shown to reduce RHAs.<sup>28, 29</sup>  
187 The intervention components included in these studies vary, making it difficult to  
188 assess the effectiveness of individual components. For example, is it post-discharge  
189 follow-up at home, or is it having re-ablement services<sup>30</sup> in place that makes a  
190 difference? It is also possible that those selected for supported discharge have been  
191 identified by extreme events and exacerbations, which might return to normal without  
192 active intervention.

193 Medicines-related risks were not found to be strongly associated with future RHAs in  
194 the multivariable logistic regression. Previous studies have found that polypharmacy,  
195 high risk medication, and diuretic use were associated with hospital readmission.<sup>31-34</sup>  
196 However, these studies did not take account of number of comorbidities, supported  
197 discharge and deprivation index in their multivariate logistic regressions.<sup>31-34</sup> This  
198 study is the first, to our knowledge, which looks comprehensively at a multitude of  
199 medication-related risk factors and their contributions towards repeated hospital  
200 admission in the elderly. It is also one of few studies looking at this topic within the  
201 NHS.

202 The number of comorbidities in this context may be driving repeated hospital  
203 admissions due to its complexity, instability, and management burden. Medicines-  
204 related factors were significant only at univariate analysis, which it begs the question  
205 of the role of medicines in this cohort of patients with multimorbidity – is medicines  
206 beneficial, neutral or harmful? It is likely that hyper-polypharmacy adds to the  
207 complexity and burden of management; ‘when required’ medicines adds to the  
208 instability of medicines regimen; PIM and high risk medicines adds to all of the  
209 above. As the number of comorbidities in an individual is non-modifiable, one could  
210 argue that more support could be given at discharge to individuals with  
211 multimorbidity or medicines regimen simplified to reduce RHA risks. The role of  
212 deprescribing and medication review in frail elderly patients should be further  
213 explored. Emerging evidence endorses the safety and positive outcomes of  
214 simultaneous discontinuation of multiple medications in older people<sup>35, 36</sup>.  
215 Importantly, previous studies have shown that older people have the desire to  
216 reduce tablet burden, particularly if they take large number of medications, or if they  
217 are experiencing side effects.<sup>37</sup> In addition, closer monitoring of adverse effects of  
218 diuretics and other high risk medicines is important to ensure safe use of these

473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531

219 medicines. Lastly, enhancing the label instructions and patient education on the use  
220 of PRN medicines may help to reduce RHAs.

221 This study was the first study of its kind to examine multiple medication-related risk  
222 factors and their association with RHAs in a given timeframe. However, there were  
223 several limitations. Firstly, the integrity of the routinely collected data cannot be  
224 guaranteed. However, as this study uses data derived from electronic discharge  
225 summaries, clinical checking systems were in place to ensure the greatest accuracy  
226 possible. Secondly, the generalisability of our findings may be limited due to its  
227 conduct at a single hospital, although prevalence of medication-related risk factors  
228 was consistent with findings from other studies. Thirdly, participants' adherence to  
229 their medication prior to and after their hospitalisation was not assessed and any  
230 non-adherence could affect the observed associations between medication exposure  
231 and adverse outcomes. Lastly, even with inclusion of known confounders in our  
232 model, residual confounding, particularly due to medication indication, condition  
233 severity, and other unrecognised factors, may affect the observed associations  
234 between medication-related risk factors and RHAs.

#### 235 236 Conclusion:

237  
238 This is the first study to evaluate a combination of medication-related risk factors in  
239 predicting RHAs in the elderly. No association was found between medicines-related  
240 risks and RHAs in a multivariable logistic regression. However, the number of  
241 comorbidities and non-supported discharge was associated with RHAs. There may  
242 be scope to define the number of comorbid conditions needed to warrant supported  
243 discharge. In addition, interventions designed to reduce number of medicines and  
244 enhance safety of prescriptions e.g. deprescribing and increased monitoring;  
245 alongside increased patient education of management of PRN medicines could have  
246 a role in reducing repeated hospital admissions in the elderly. Further work is  
247 required to develop and evaluate risk prediction tools which incorporate medicines-  
248 related risks; along with targeted interventions to reduce medication-related RHAs.

249  
250

251 Funding: This research was supported by a Doctoral Training Grant by the  
252 Pharmacy Department at Sheffield Teaching Hospitals Foundation Trust.

253  
254  
255

256 Word count = 3625 – (tables = 562) = 3170 – table subheadings (65) = 2998

532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590

## References

1. Blunt I, Bardsley M, Dixon J. Trends in emergency admissions in England 2004–2009: is greater efficiency breeding inefficiency? *Emergency*. 2000;1000:0.
2. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *The Lancet*. 2012;380:37-43.
3. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. *Ageing research reviews*. 2011;10:430-439.
4. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *Bmj*. 2004;329:15-19.
5. Stefan MS, Pekow PS, Nsa W, et al. Hospital performance measures and 30-day readmission rates. *Journal of general internal medicine*. 2013;28:377-385.
6. Aubert CE, Schnipper JL, Williams MV, et al. Simplification of the HOSPITAL score for predicting 30-day readmissions. *BMJ Qual Saf*. 2017;26:799-805.
7. Department of Health. Equity and excellence: Liberating the NHS. London 2010.
8. Fylan B, Tranmer M, Armitage G, Blenkinsopp A. Cardiology patients' medicines management networks after hospital discharge: A mixed methods analysis of a complex adaptive system. *Research in Social and Administrative Pharmacy*. 2018.
9. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. *Archives of internal medicine*. 2008;168:1890-1896.
10. Morse A. Emergency admissions to hospital: managing the demand. London: National Audit Office. 2013.
11. Kansagara D, Englander H, Salanitro A, et al. Risk prediction models for hospital readmission: a systematic review. *Jama*. 2011;306:1688-1698.
12. Dorajoo SR, See V, Chan CT, et al. Identifying Potentially Avoidable Readmissions: A Medication-Based 15-Day Readmission Risk Stratification Algorithm. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2017;37:268-277.
13. Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. Validity and reliability of the Edmonton Frail Scale. *Age and ageing*. 2006;35:526-529.
14. RANDOM.ORG. True Random Number Service. Vol 2016.
15. Public Health GIS Unit. Life Expectancy in Sheffield, UK. Vol 2018.
16. Howard R, Avery A, Howard P, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. *Quality & safety in health care*. 2003;12:280-285.
17. American Geriatrics Society. Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *Journal of the American Geriatrics Society*. 2015;63:2227-2246.
18. Sino CG, Stuffken R, Heerdink ER, Schuurmans MJ, Souverein PC, Egberts TAC. The association between prescription change frequency, chronic disease score and hospital admissions: a case control study. *BMC Pharmacology and Toxicology*. 2013;14:39.
19. Alldred D, Barber N, Buckle P, et al. Care Home Use of Medicines Study (CHUMS). Medication Errors in Nursing and Residential Care Homes: Prevalence, Consequences, Causes and Solutions. *Report to the Patient Safety Research Portfolio*. 2009.
20. Gnjidic D, Le Couteur DG, Pearson S-A, et al. High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. *BMC Public Health*. 2013;13:115.
21. Masnoon N, Shakib S, Kalisch L, Caughey G. Systematic review of polypharmacy definition, assessment tools, and association with clinical outcomes. *Research in Social and Administrative Pharmacy*. 2017;13:e28-e29.

591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649

- 307 **22.** Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number  
308 of events per variable in logistic regression analysis. *Journal of clinical epidemiology*.  
309 1996;49:1373-1379.
- 310 **23.** Zhang M, Holman CDAJ, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. Comorbidity and  
311 repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort  
312 study. *Bmj*. 2009;338:a2752.
- 313 **24.** van Walraven C, Dhalla IA, Bell C, et al. Derivation and validation of an index to predict early  
314 death or unplanned readmission after discharge from hospital to the community. *Canadian*  
315 *Medical Association Journal*. 2010;182:551-557.
- 316 **25.** Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA. Epidemiology and impact of  
317 multimorbidity in primary care: a retrospective cohort study. *Br J Gen Pract*. 2011;61:e12-  
318 e21.
- 319 **26.** Yarnall AJ, Sayer AA, Clegg A, Rockwood K, Parker S, Hindle JV. New horizons in  
320 multimorbidity in older adults. *Age and ageing*. 2017;46:882-888.
- 321 **27.** Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *The lancet*.  
322 2013;381:752-762.
- 323 **28.** Laugaland K, Aase K, Barach P. Interventions to improve patient safety in transitional care—a  
324 review of the evidence. *Work*. 2012;41:2915-2924.
- 325 **29.** Garcia-Caballeros M, Ramos-Diaz F, Jimenez-Moleon JJ, Bueno-Cavanillas A. Drug-related  
326 problems in older people after hospital discharge and interventions to reduce them. *Age and*  
327 *Ageing*. 2010;39:430-438.
- 328 **30.** Parsons M, Senior HEJ, Kerse N, et al. The Assessment of Services Promoting Independence  
329 and Recovery in Elders Trial (ASPIRE): a pre-planned meta-analysis of three independent  
330 randomised controlled trial evaluations of ageing in place initiatives in New Zealand. *Age*  
331 *and Ageing*. 2012;41:722-728.
- 332 **31.** Ruiz B, García M, Aguirre U, Aguirre C. Factors predicting hospital readmissions related to  
333 adverse drug reactions. *European journal of clinical pharmacology*. 2008;64:715-722.
- 334 **32.** Picker D, Heard K, Bailey TC, Martin NR, LaRossa GN, Kollef MH. The number of discharge  
335 medications predicts thirty-day hospital readmission: a cohort study. *BMC health services*  
336 *research*. 2015;15:282.
- 337 **33.** Davies EC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. Emergency re-admissions to  
338 hospital due to adverse drug reactions within 1 year of the index admission. *British journal of*  
339 *clinical pharmacology*. 2010;70:749-755.
- 340 **34.** Nair NP, Chalmers L, Bereznicki BJ, Curtain CM, Bereznicki LR. Repeat Adverse Drug Reaction-  
341 Related Hospital Admissions in Elderly Australians: A Retrospective Study at the Royal  
342 Hobart Hospital. *Drugs & aging*. 2017;34:777-783.
- 343 **35.** Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of  
344 multiple medications in older adults: addressing polypharmacy. *Archives Of Internal*  
345 *Medicine*. 2010;170:1648-1654.
- 346 **36.** Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in frail older people: a randomised  
347 controlled trial. *PLoS One*. 2016;11:e0149984.
- 348 **37.** Sirois C, Ouellet N, Reeve E. Community-dwelling older people's attitudes towards  
349 deprescribing in Canada. *Research in Social and Administrative Pharmacy*. 2017;13:864-870.

650  
651  
652  
653 355  
654 356  
655  
656 357  
657 358  
658 359  
659 360  
660 361  
661 362  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708

**The dataset used to generate this manuscript will be used in the main author's PhD Thesis, which will be published on a public repository. It is anticipated that the dataset will not be used to generate further manuscripts.**

## **AUTHOR DECLARATION/ AGREEMENT**

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). She is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from [v.cheong@bradford.ac.uk](mailto:v.cheong@bradford.ac.uk)

Approved and agreed by all authors as follows:

Dr Julie Sowter

Dr Jonathan Silcock

Dr Neil Hamilton

Dr Ali Ali

Mr Andy Scally

Ms V-Lin Cheong